Headache after evaluation with transcranial magnetic stimulation in a healthy participant. Case report

Cefaleia após avaliação com estimulação magnética transcraniana em participante saudável. Relato de caso

Julie Azevedo Araújo Valente¹, Maria José Pedreira Ramalho², Janine Ribeiro Camatti³, Abrahão Fontes Baptista⁴

DOI 10.5935/2595-0118.20190054

ABSTRACT

BACKGROUND AND OBJECTIVES: Adverse effects during noninvasive stimulation of the brain are rare events. The objective of this study is to present a patient's case with an intense headache with autonomic signs after single-pulse transcranial magnetic stimulation.

CASE REPORT: A 28-year old female patient, volunteered to participate in a study on the evaluation of motor cortical excitability after the injection of lidocaine in the first dorsal interosseous muscle. The resting motor threshold was estimated at four moments: before the procedure, immediately after the procedure, 30 minutes, and one hour after the procedure. At the end of the experiment, 240 pulses were performed. The participant reported mild-intensity headache that rapidly progressed to severe, left hemicranial headache, the same region where the transcranial magnetic stimulation pulses were applied. In association with the pain, she had nausea, vomiting, photophobia, conjunctival hyperemia, lacrimation, and ipsilateral eyelid edema, requiring emergency care.

CONCLUSION: It is possible that supraliminal intensities (>100% of resting motor threshold) in single-pulse transcranial magnetic stimulation may predispose to adverse effects. Other factors such as skull anatomy, electrical impedance, age, gender, cognitive and affective status, use of medications, hormone levels, the concentration of neurotransmitters and receptor expression, genetic factors and the circadian cycle may also be involved. There are no well-established safety models to guide assessment

Julie Azevedo Araújo Valente - Ohttps://orcid.org/0000-0001-7417-9961; Maria José Ramalho - Ohttps://orcid.org/0000-0002-4450-8565; Janine Ribeiro Camatti - Ohttps://orcid.org/0000-0002-5726-8388; Abrahão Fontes Baptista - Ohttps://orcid.org/0000-0001-7870-3820.

1. Hospital São Rafael, Clínica da Dor, Salvador, BA, Brasil.

2. Hospital São Rafael, Departamento de Anestesiologia, Salvador, BA, Brasil.

3. Universidade Federal do ABC, Departamento de Neurociência e Cognição, São Bernardo do Campo, SP, Brasil.

4. Universidade Federal do ABC, Centro de Matemática, Computação e Cognição, São Bernardo do Campo, SP, Brasil.

Submitted on May 15, 2019. Accepted for publication on July 16, 2019. Conflict of interests: none – Sponsoring sources: none.

Correspondence to:

Rua dos Corais, 679, Residencial Estrela do Mar, Alphaville 1 41701-080 Salvador, BA, Brasil. E-mail: julieazvalente@gmail.com julie_az@hotmail.com

© Sociedade Brasileira para o Estudo da Dor

protocols with single-pulse transcranial magnetic stimulation, considered a technique with a low incidence of adverse effects and with little demand for safety studies.

Keywords: Case report, Headache, Transcranial magnetic stimulation.

RESUMO

JUSTIFICATIVA E OBJETIVOS: Efeitos adversos durante a estimulação não invasiva do cérebro são eventos considerados raros. O objetivo deste estudo foi apresentar um caso de paciente com cefaleia intensa com sinais autonômicos após estimulação magnética transcraniana de pulso único.

RELATO DO CASO: Paciente do sexo feminino, 28 anos, saudável, voluntariamente se apresentou para participar de pesquisa sobre avaliação de excitabilidade cortical motora após a realização de injeção de lidocaína no músculo primeiro interósseo dorsal. O limiar motor em repouso foi estimado em quatro momentos: antes do procedimento, imediatamente após o procedimento, 30 minutos e uma hora após o procedimento. Foram realizados ao final do experimento 240 pulsos. A participante referiu cefaleia, de leve intensidade, que rapidamente progrediu para cefaleia intensa, hemicraniana à esquerda, na região onde os pulsos da estimulação magnética transcraniana foram aplicados. Em associação à dor, apresentou náuseas, vômitos, fotofobia, hiperemia conjuntival, lacrimejamento e edema palpebral ipsilaterais, com necessidade de atendimento em unidade de emergência.

CONCLUSÃO: É possível que intensidades supralimiares (>100% do limiar motor em repouso) em estimulação magnética transcraniana de pulso único possam predispor a efeitos adversos. Outros fatores como anatomia do crânio, impedância elétrica, idade, sexo, estado cognitivo e afetivo, uso de fármacos, níveis hormonais, concentração de neurotransmissores e expressão de receptores, fatores genéticos e ciclo circadiano também podem ser implicados. Não há modelos de segurança bem estabelecidos para guiar protocolos de avaliação com estimulação magnética transcraniana de pulso único, considerada uma técnica com baixa incidência de efeitos adversos e com baixa demanda de atenção de estudos sobre segurança.

Descritores: Cefaleia, Estimulação magnética transcraniana, Relato de caso.

INTRODUCTION

Transcranial Magnetic Stimulation (TMS) is based on the principle of electromagnetic induction of an electric field on

the skull surface of sufficient magnitude to trigger the depolarization of cortical neurons. Adverse effects during noninvasive brain stimulation are considered rare events¹, especially during the administration of single- and paired-pulses, techniques used to assess cortical excitability^{1,2}. Studies using single-pulse TMS can assess central motor conduction time and causal chronometry in brain-behavior relations¹. The use of the paired-pulse allows the assessment of intracortical facilitation and inhibition measures, as well as the study of cortico-cortical interactions¹. The occurrence of mild and transient headache, hearing impairment, neck pain, and toothache are considered possible adverse effects with these techniques³. Seizures, acute hypomania, histotoxicity, cognitive, brain and hormonal changes, such as elevated TSH and lactate levels, have not been described in studies with single- and paired-pulse TMS, although they have been reported during high-frequency repetitive transcranial magnetic stimulation (rTMS) and theta-burst protocols³.

This study aimed to present a case of severe headache with autonomic signs after single-pulse TMS in a healthy young woman.

CASE REPORT

Right-handed, white, 28-year-old female patient volunteered to participate in research at the functional electrostimulation laboratory of the Federal University of Bahia (UFBA), to assess the motor cortical excitability after injection of lidocaine in the first dorsal interosseous muscle. After applying a safety questionnaire and signing the Free and Informed Consent Form, this participant was included in the study. She denied a history of comorbidities, drug use, recreational drugs, recent caffeine or cigarette consumption, sleep deprivation, implantable brain devices, seizure history, and pregnancy. When asked about the date of her last period, she could not remember the exact date, but said she was in the ovulatory period. This participant had previously volunteered in other studies involving TMS assessment without any complications.

Cortical excitability and organization were assessed with a TMS device (BIStim, Magstim, Reino Unido). After cleaning with alcohol and abrasive solution, the self-adhesive electromyography (EMG) electrodes (Miotec, Brasil) were placed on the muscular belly of the first dorsal interosseous (FDI), abductor pollicis brevis (APB) and abductor digiti minimi (ADM) muscles of the participant's right (dominant) hand, which was comfortably seated in a chair, and kept awake throughout the assessment protocol. A polyester cap previously marked with a 1x1cm grid oriented in the Cartesian plane was placed on the participant's head and served as a reference for hotspot marking. An eight-coil was used on the surface of the left frontoparietal region, corresponding to the primary motor cortex. Monophasic paired- and single- pulses were administered every six seconds, and EMG activity was amplified and converted to digital signal (1401 and 1902, CED, Reino Unido) and monitored in real-time using Signal software (CED, Reino Unido). The average of 5 pulses in points under the described region was used to identify the hotspot, aiming to obtain the best response in motor evoked potential (MEP) size in the FDI muscle. After this step, the resting motor threshold (RMT) was determined, considering the lower intensity of the device to generate a MEP peak-to-peak with an amplitude of 50 μ Volts. This threshold was estimated at four moments: before the procedure, immediately after, 30 minutes and one hour after the procedure. In each of these moments, 60 pulses were distributed randomly between 20 pulses at 100% of the RMT, related to MEP; 20 pulses at 80% of the RMT, with 2ms intervals, corresponding to the short-term intracortical inhibition measure, and 20 pulses at 120% of the RMT, with 15ms intervals, relative to the Intracortical Facilitation estimates, totaling at the end of the experiment 240 pulses.

The procedure, performed by an anesthesiologist, was chosen randomly by drawing sealed envelopes. The participant underwent dry needling in the FDI muscle of the dominant hand, and no substance was injected (Table 1).

Table 1. Electrophysiological measurements obtained by transcra-nial magnetic stimulation before and after dry needling in the firstdorsal interosseous muscle of the dominant hand

	Baseline	Immediately after needling	30 min after needling	1h after needling
RMT	50	52	51	48
80% of RMT	40	42	41	38
120% of RMT	59	63	61	58

RMT = resting motor threshold.

During pulse application, the participant did not report any complaints. However, in the first minute after the end of the last data collection, the participant reported a mild headache that rapidly progressed to severe, left hemicrania headache. In association with headache, she presented nausea, photophobia, conjunctival hyperemia, tearing, and ipsilateral eyelid edema. She denied similar previous episodes, but reported an irregular history of premenstrual headache (mean of three to four episodes per year), however, without medical follow-up. Two anesthesiologists and two physical therapists were present during the collection and provided care to the participant, who was placed in a horizontal supine position on a stretcher and had vital signs checked within normal limits. Dipyrone was administered orally. The participant was observed for approximately 60 minutes, until she reported headache improvement, and was then released and advised to contact the medical team involved in the research if symptoms returned. A few hours after being released, the participant presented headache return, with the same characteristics as before, but at this moment, accompanied by nausea and vomiting. She was instructed to use naproxen (500mg), cyclobenzaprine (5mg) and ondansetron (4mg) orally, with complete relief of symptoms, as well as outpatient follow-up with a neurologist. Two days after the event, the participant had her menstrual flow. The investigation was performed by cranial nuclear magnetic resonance and electroencephalogram without changes.

DISCUSSION

The use of TMS devices has become increasingly common in both basic research and clinical therapies². In the application of repetitive transcranial magnetic stimulation (rTMS), many safety parameters are suggested, such as the total number of pulses, duration, and intervals between pulses, intervals between stimulation sessions, coil type, and stimulation site³. In the application of single-pulse TMS, the pulse amplitude, in theory, does not cause therapeutic changes. Therefore, there are no well-established safety models to guide assessment protocols with single-pulse TMS, considered a technique with a low incidence of adverse effects and low attention demand from safety studies⁴. However, there are studies reporting adverse effects when supraliminal intensities (>100% of the RMT) are used in single-pulse TMS⁵. Moreover, more than just technical requirements, other factors can influence the response of TMS, being much more difficult to control, but no less important: skull anatomy, electrical impedance, age, gender, cognitive and affective state, drug use, hormone levels, neurotransmitter concentration and receptor expression, genetic factors and circadian cycle⁵.

Headache in single-pulse TMS protocols is considered a rare occurrence and little described in the literature⁶. In the last study on the safety and TMS, it was described that the presence of neck pain, toothache, and discomfort under the region where the coil is positioned are possible to occur with single pulses¹. A study published in 2013 compared the incidence of adverse effects between single-pulse TMS and rTMS with results different from those described in the literature⁷. In this work, the incidence of adverse effects was more frequent in single-pulse protocols. The suggested explanation for this occurrence is the participant profile of single-pulse TMS protocols, often naive or with fantasies regarding the mechanism of action of TMS⁸. In the case of headache occurring in this case report, this argument cannot be applied since the participant had already participated in other study protocols, and she was aware of the TMS effects. The occurrence of trigeminal headache, with signs and symptoms very similar to those presented by the participant in this study, was described after the application of rTMS⁹ protocol.

In this specific case, the etiology can be established by a therapeutic test performed with the administration of oxygen and immediate relief of symptoms. The diagnosis of the type of headache presented by the participant, whether trigeminal headache or migraine with autonomic signs¹⁰ was impaired in this report since the data collection was performed in an out-of-hospital unit and without the presence of a neurologist. Thus, there was impairment in the assessment of the case, since the differential diagnosis was made retrospectively.

CONCLUSION

Although rare, adverse effects are possible with the use of single-pulse TMS. It is critical that researchers be familiar with the most common occurrences to identify and follow up with each case.

REFERENCES

- Groppa S, Oliviero A, Eisen A, Quartarone A, Cohen LG, Mall V, et al. A practical guide to diagnostic transcranial magnetic stimulation: Report of an IFCN committee. Clin Neurophysiol. 2012;123(5):858-82.
- Cavaleri R, Schabrun SM, Chipchase LS. The number of stimuli required to reliably assess corticomotor excitability and primary motor cortical representations using transcranial magnetic stimulation (TMS): a systematic review and meta-analysis. Syst Rev. 2017;6(1):48.
- Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120(12):2008-39.
- Chen R, Tam A, Bütefisch C, Corwell B, Ziemann U, Rothwell JC, et al. Intracortical inhibition and facilitation in different representations of the human motor cortex. J Neurophysiol. 1998;80(6):2870-81.
- Peterchev AV, Wagner TA, Miranda PC, Nitsche MA, Paulus W, Lisanby SH, et al. Fundamental of transcranial electric and magnetic stimulation dose: definition, selection, and reporting practices. Brain Stimul. 2012;5(4):435-53.
- Auriat AM, Neva JL, Peters S, Ferris JK, Boyd LA. A review of transcranial magnetic stimulation and multimodal neuroimaging to characterize post-stroke neuroplasticity. Front Neurol. 2015;6:226.
- Maizey L, Allen CP, Dervinis M, Verbruggen F, Varnava A, Kozlov M, et al. Comparative incidence rates of mild adverse effects to transcranial magnetic stimulation. Clin Neurophysiol. 2013;124(3):536-44.
- Tajerian M, Leu D, Zou Y, Sahbaie P, Li W, Khan H, et al. Brain neuroplastic changes accompany anxiety and memory deficits in a model of complex regional pain syndrome. Anesthesiology. 2014;121(4):852-65.
- Durmaz O, Ateş MA, Şenol MG. Repetitive transcranial magnetic stimulation (rTMS)induced trigeminal autonomic cephalalgia. Noro Psikiyatri Arş. 2015;52(3):309-11.
- Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: a safety review. Headache. 2010;50(7):1153-63.